Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $33.2 million.

  • Stoke Therapeutics' Change in Acquisitions & Divestments rose 6575.5% to $33.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.2 million, marking a year-over-year increase of 18706.89%. This contributed to the annual value of $60.0 million for FY2024, which is 4421.82% down from last year.
  • As of Q3 2025, Stoke Therapeutics' Change in Acquisitions & Divestments stood at $33.2 million, which was up 6575.5% from $33.2 million recorded in Q2 2025.
  • Stoke Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $79.0 million during Q3 2022, with a 5-year trough of $9.0 million in Q1 2022.
  • Over the past 4 years, Stoke Therapeutics' median Change in Acquisitions & Divestments value was $27.2 million (recorded in 2023), while the average stood at $30.4 million.
  • Per our database at Business Quant, Stoke Therapeutics' Change in Acquisitions & Divestments skyrocketed by 49166.67% in 2023 and then tumbled by 8122.07% in 2024.
  • Quarter analysis of 4 years shows Stoke Therapeutics' Change in Acquisitions & Divestments stood at $18.0 million in 2022, then decreased by 16.8% to $15.0 million in 2023, then surged by 100.0% to $30.0 million in 2024, then increased by 10.5% to $33.2 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $33.2 million for Q3 2025, versus $33.2 million for Q2 2025 and $32.8 million for Q1 2025.